Literature DB >> 18322666

[Obesity and heart failure].

S Frantz1, M Fassnacht, B Allolio, J Bauersachs.   

Abstract

Obesity doubles the risk of heart failure independent of comorbidities like hypertension or coronary artery disease potentially mediated by altered hemodynamics to compensate increased mass and metabolic activity. Symptoms of obesity cardiomyopathy do not differ from other forms of cardiomyopathy, but may be easily mixed up with obesity associated symptoms. The diagnosis can be made with imaging techniques like echocardiography or magnetic resonance imaging. Therapeutic approaches include weight control by dietary intervention and exercise, as well as bariatric surgery for the morbidly obese. Heart failure treatment should otherwise follow the general heart failure guidelines.

Entities:  

Mesh:

Year:  2008        PMID: 18322666     DOI: 10.1007/s00108-008-2052-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  17 in total

Review 1.  Obesity and the heart a weighty issue.

Authors:  Stephan von Haehling; Wolfram Doehner; Stefan D Anker
Journal:  J Am Coll Cardiol       Date:  2006-05-15       Impact factor: 24.094

Review 2.  Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America.

Authors:  Lidia S Szczepaniak; Ronald G Victor; Lelio Orci; Roger H Unger
Journal:  Circ Res       Date:  2007-10-12       Impact factor: 17.367

3.  Effects of weight loss after gastric bypass on right and left ventricular function assessed by tissue Doppler imaging.

Authors:  Howard J Willens; Simon C Chakko; Patricia Byers; Julio A Chirinos; Eugenio Labrador; Juan C Castrillon; Maureen H Lowery
Journal:  Am J Cardiol       Date:  2005-06-15       Impact factor: 2.778

4.  Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.

Authors:  W P James; A Astrup; N Finer; J Hilsted; P Kopelman; S Rössner; W H Saris; L F Van Gaal
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

5.  [Epidemiology of left ventricular systolic dysfunction in the general population of Germany: results of an echocardiographic study of a large population-based sample].

Authors:  M Fischer; A Baessler; S R Holmer; M Muscholl; U Bröckel; A Luchner; H-W Hense; A Döring; G Riegger; H Schunkert
Journal:  Z Kardiol       Date:  2003-04

6.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Authors:  J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

7.  B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures.

Authors:  Jennifer A Taylor; Robert H Christenson; Krishnamurti Rao; Melinda Jorge; Stephen S Gottlieb
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

Review 8.  Obesity cardiomyopathy: diagnosis and therapeutic implications.

Authors:  Chiew Wong; Thomas H Marwick
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2007-09

Review 9.  Obesity cardiomyopathy: pathogenesis and pathophysiology.

Authors:  Chiew Wong; Thomas H Marwick
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2007-08

10.  Obesity and suppressed B-type natriuretic peptide levels in heart failure.

Authors:  Mandeep R Mehra; Patricia A Uber; Myung H Park; Robert L Scott; Hector O Ventura; Bobbett C Harris; Edward D Frohlich
Journal:  J Am Coll Cardiol       Date:  2004-05-05       Impact factor: 24.094

View more
  1 in total

1.  [Obesity and heart failure].

Authors:  D Weismann; S Wiedmann; M Bala; S Frantz; M Fassnacht
Journal:  Internist (Berl)       Date:  2015-02       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.